Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free KTTAW Stock Alerts

Pasithea Therapeutics (KTTAW) Competitors

$0.0047 +0.00 (+2.19%)
As of 06/3/2026 03:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

KTTAW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Pasithea Therapeutics stock or one of its competitors? MarketBeat compares Pasithea Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pasithea Therapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Pasithea Therapeutics compare to Ainos?

Pasithea Therapeutics (NASDAQ:KTTAW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/AN/AN/AN/A
Ainos$18.11KN/AN/AN/AN/A

In the previous week, Ainos had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 1 mentions for Ainos and 0 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.89 beat Ainos' score of 1.43 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Pasithea Therapeutics Very Positive
Ainos Positive

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A N/A N/A
Ainos N/A N/A N/A

Summary

Ainos beats Pasithea Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Alvotech?

Pasithea Therapeutics (NASDAQ:KTTAW) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

In the previous week, Pasithea Therapeutics' average media sentiment score of 1.89 equaled Alvotech'saverage media sentiment score.

Company Overall Sentiment
Pasithea Therapeutics Very Positive
Alvotech Very Positive

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/AN/AN/AN/A
Alvotech$586.32MN/AN/AN/AN/A

Summary

Alvotech beats Pasithea Therapeutics on 1 of the 1 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Aravive?

Aravive (NASDAQ:ARAV) and Pasithea Therapeutics (NASDAQ:KTTAW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

In the previous week, Pasithea Therapeutics' average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
Pasithea Therapeutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
Pasithea TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
Pasithea Therapeutics N/A N/A N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Aravive beats Pasithea Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Pasithea Therapeutics (NASDAQ:KTTAW) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
Pasithea TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
Pasithea Therapeutics N/A N/A N/A

In the previous week, Pasithea Therapeutics' average media sentiment score of 1.89 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
Pasithea Therapeutics Very Positive

Summary

Pasithea Therapeutics beats Atlantic Coastal Acquisition Corp. II on 1 of the 1 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Pasithea Therapeutics (NASDAQ:KTTAW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

In the previous week, Pasithea Therapeutics' average media sentiment score of 1.89 beat Biofrontera's score of 1.87 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Very Positive
Pasithea Therapeutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Pasithea TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Pasithea Therapeutics N/A N/A N/A

Summary

Biofrontera and Pasithea Therapeutics tied by winning 1 of the 2 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KTTAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KTTAW vs. The Competition

Export
MetricPasithea TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$375.47M$6.32B$12.38B
Dividend YieldN/A3.87%2.69%5.31%
P/E RatioN/A3.2123.7324.35
Price / SalesN/A6,680.81498.7895.26
Price / CashN/A13.1341.3955.53
Price / BookN/A84.219.966.72
Net IncomeN/A-$96.07M$3.56B$337.03M
7 Day PerformanceN/A-0.92%-1.04%-0.16%
1 Month PerformanceN/A1.96%2.18%3.74%
1 Year PerformanceN/A75.42%28.93%34.34%

Pasithea Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KTTAW
Pasithea Therapeutics
N/A$0.00
+2.2%		N/A-74.8%$0.00N/AN/A3
AIMDW
Ainos
N/A$0.14
+25.6%		N/A-18.5%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.17
-31.1%		N/A-92.3%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
+13.6%		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KTTAW) was last updated on 6/5/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
Elon’s AI supercomputer just went live. Here’s my #1 stock.
Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...
InvestorPlace | Sponsoredtc pixel